Results 1 to 10 of about 1,098,931 (194)

The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström’s Macroglobulinemia [PDF]

Clinical Hematology International, 2022
The use of Bruton Tyrosine Kinase (BTK) inhibitors in Waldenström’s Macroglobulinemia (WM) is evolving. Ibrutinib, a first-generation BTK inhibitor, is currently approved for use in frontline and relapsed/refractory disease.
Obada Ababneh, Hassan Abushukair, Aref Qarqash, Sebawe Syaj, Samer Al Hadidi   +4 more
doaj   +4 more sources

Chinese expert consensus on Bruton tyrosine kinase inhibitors in the treatment of B-cell malignancies [PDF]

Experimental Hematology & Oncology, 2023
Targeted therapy with Bruton tyrosine kinase (BTK) inhibitors have revolutionized the treatment of patients with various B-cell malignancies. BTK inhibitors such as ibrutinib, zanubrutinib, orelabrutinib, and acalabrutinib have shown good clinical ...
Yuqin Song, Shang-Ju Wu, Zhixiang Shen, Donglu Zhao, Thomas Sau Yan Chan, Huiqiang Huang, Lugui Qiu, Jianyong Li, Tran-der Tan, Jun Zhu, Yongping Song, Wei-Han Huang, Weili Zhao, Herman Sung Yu Liu, Wei Xu, Naizhi Chen, Jun Ma, Cheng-Shyong Chang, Eric Wai Choi Tse   +18 more
doaj   +3 more sources

Translational autoimmunity in pemphigus and the role of novel Bruton tyrosine kinase inhibitors [PDF]

Journal of Translational Autoimmunity, 2022
Bruton tyrosine kinase (BTK) is involved in a multifarious inflammatory and autoimmune process. As a result, BTK has emerged as a promising novel remedial target for amalgamated autoimmune diseases.
Piyu Parth Naik
doaj   +3 more sources

Bruton tyrosine kinase inhibitors as potential therapeutic agents for COVID-19: A review

Metabolism Open, 2021
Coronavirus disease 2019 (COVID-19) is first detected in December 2019 in Wuhan, China which is a new pandemic caused by SARS-COV-2 that has greatly affected the whole world.
Zemene Demelash Kifle
exaly   +3 more sources

Bruton tyrosine kinase inhibitors in B-cell lymphoma: beyond the antitumour effect [PDF]

Experimental Hematology & Oncology, 2022
Targeting B-cell receptor signalling using Bruton tyrosine kinase (BTK) inhibitors (BTKis) has become a highly successful treatment modality for B-cell malignancies, especially for chronic lymphocytic leukaemia. However, long-term administration of BTKis
Haoran Wang, Hao Guo, Jingyi Yang, Yanyan Liu, Xingchen Liu, Qing Zhang, Keshu Zhou   +6 more
doaj   +2 more sources

Real-world comparative effectiveness of Bruton tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma [PDF]

Blood Advances
: This real-world retrospective cohort study evaluated utilization and comparative effectiveness of covalent Bruton tyrosine kinase inhibitor (cBTKi) monotherapies in relapsed/refractory mantle cell lymphoma (R/R MCL) from electronic health records in ...
Tycel Phillips, Mengyang Di, Taavy A. Miller, Jingru Wang, Amy Pierre, Gregory A. Maglinte, Erlene K. Seymour, Yucai Wang   +7 more
doaj   +2 more sources

High-risk stays high-risk: Bruton tyrosine kinase inhibitors in B-cell malignancies [PDF]

Haematologica
Not available.
Othman Al-Sawaf
doaj   +2 more sources

Real-World Outcomes Among Medicare Beneficiaries Treated with Bruton Tyrosine Kinase Inhibitors for Treatment-Naïve CLL [PDF]

Oncology and Therapy
Introduction There is a dearth of head-to-head studies comparing covalent Bruton tyrosine kinase (cBTK) inhibitors in adults with chronic lymphocytic leukemia (CLL).
Daniel A. Ermann, Deborah M. Stephens, Xiaoliang Wang, Irene Varghese, Heidi De Souza, Caitlin Sheetz, Qianhong Fu, Gregory A. Maglinte, Rhys Williams, Erlene K. Seymour, Derrick van Beuge, Mazyar Shadman, Ryan Jacobs   +12 more
doaj   +2 more sources

Bruton tyrosine kinase inhibitors in combination with chemoimmunotherapy is an effective treatment for patients with Richter’s syndrome [PDF]

Leukemia Research Reports
Richter’s syndrome (RS) is characterized by transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) into an aggressive lymphoma.
Tristan Meier, Giovann Huynh, Ernesto Ayala, Han W. Tun, Madiha Iqbal   +4 more
doaj   +2 more sources

Comparative efficacy of Bruton tyrosine kinase inhibitors in high-risk relapsed/refractory CLL: a network meta-analysis [PDF]

Blood Advances
: Bruton tyrosine kinase inhibitors (BTKis) have led to changes in the treatment algorithm for patients with high-risk relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), defined based on the presence of genetic mutations.
Mazyar Shadman, Jennifer R. Brown, Leyla Mohseninejad, Keri Yang, Heather Burnett, Binod Neupane, Rhys Williams, Nicole Lamanna, Susan M. O'Brien, Alessandra Tedeschi, Constantine S. Tam   +10 more
doaj   +2 more sources